Table 3.
Phenylephrine Concentration, μg·min−1·dl thigh volume−1 |
|||||||
---|---|---|---|---|---|---|---|
BL | Propranolol (5 mg) | 0.015 | 0.03 | 0.06 | 0.12 | 0.24 | |
Control | |||||||
Leg blood flow, ml/min | 253 ± 33 | 227 ± 33# | 212 ± 33 | 185 ± 33# | 174 ± 33# | 142 ± 24# | 141 ± 19# |
Leg vascular conductance, ml·min−1·mmHg−1 | 3.0 ± 0.4 | 2.7 ± 0.4# | 2.5 ± 0.4 | 2.2 ± 0.4# | 2.1 ± 0.4# | 1.6 ± 0.3# | 1.6 ± 0.2# |
Leg perfusion pressure, mmHg | 85 ± 3 | 85 ± 3 | 83 ± 3 | 84 ± 3 | 85 ± 3 | 86 ± 3 | 87 ± 3 |
CFA diameter | |||||||
cm | 1.02 ± 0.06 | 1.02 ± 0.06 | 1.01 ± 0.06 | 0.99 ± 0.06# | 0.97 ± 0.07# | 0.97 ± 0.07# | 0.93 ± 0.7# |
%Δ | 0.0 ± 0.1 | −0.6 ± 0.4 | −3.0 ± 1.7 | −4.8 ± 2.5# | −6.8 ± 2.9# | −9.6 ± 3.5# | |
HR, beats/min | 60 ± 4 | 54 ± 3# | 54 ± 2 | 53 ± 3 | 53 ± 2 | 51 ± 2 | 52 ± 2 |
HFrEF | |||||||
Leg blood flow, ml/min | 218 ± 26 | 215 ± 20 | 202 ± 22 | 189 ± 19 | 179 ± 16# | 174 ± 18# | |
Leg vascular conductance, ml·min−1·mmHg−1 | 2.8 ± 0.3 | 2.8 ± 0.3 | 2.5 ± 0.3 | 2.3 ± 0.2# | 2.2 ± 0.3# | 2.1 ± 0.2# | |
Leg perfusion pressure, mmHg | 80 ± 5 | 80 ± 5 | 82 ± 5 | 82 ± 5 | 83 ± 4 | 82 ± 3 | |
CFA diameter | |||||||
cm | 0.88 ± 0.05 | 0.87 ± 0.05 | 0.86 ± 0.05 | 0.84 ± 0.05# | 0.82 ± 0.05# | 0.80 ± 0.06# | |
%Δ | −1.2 ± 0.3 | −2.6 ± 0.6 | −4.3 ± 0.8# | −6.2 ± 1.0# | −8.8 ± 2# | ||
HR, beats/min | 67 ± 2 | 65 ± 2* | 66 ± 3* | 67 ± 2* | 68 ± 3* | 72 ± 6* |
Values are means ± SE. In controls, propranolol was administered immediately before the phenylephrine dose response (0.015–0.24 μg·min−1·dl thigh volume−1, 2 min per dose) to minimize β-adrenergic effects. BL, baseline; HR, heart rate; CFA, common femoral artery; HFrEF, heart failure with reduced ejection fraction.
P < 0.05 vs. control;
P < 0.05 vs. preinfusion.